These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16037656)

  • 21. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
    Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L;
    Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Living with lost individuality. Special concerns in medical care of severely demented Alzheimer patients].
    Rajna P
    Ideggyogy Sz; 2010 Nov; 63(11-12):364-76. PubMed ID: 21413439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
    Nozawa M; Ichimiya Y; Nozawa E; Utumi Y; Sugiyama H; Murayama N; Iseki E; Arai H
    Psychogeriatrics; 2009 Jun; 9(2):50-5. PubMed ID: 19604325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?
    Vellas B; Andrieu S; Cantet C; Dartigues JF; Gauthier S
    J Nutr Health Aging; 2007; 11(4):338-41. PubMed ID: 17653494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of donepezil on memory and cognition in multiple sclerosis.
    Christodoulou C; Melville P; Scherl WF; Macallister WS; Elkins LE; Krupp LB
    J Neurol Sci; 2006 Jun; 245(1-2):127-36. PubMed ID: 16626752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
    Wattmo C; Hansson O; Wallin AK; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2008; 26(3):203-11. PubMed ID: 18769065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ginkgo and Alzheimer's disease: little or no different from placebo.
    Prescrire Int; 2007 Oct; 16(91):205-7. PubMed ID: 17926840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study.
    Rockwood K; Black S; Bedard MA; Tran T; Lussier I;
    Int J Geriatr Psychiatry; 2007 Apr; 22(4):312-9. PubMed ID: 17006874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive approach of donepezil and psychosocial interventions on cognitive function and quality of life for Alzheimer's disease: the Osaki-Tajiri Project.
    Meguro M; Kasai M; Akanuma K; Ishii H; Yamaguchi S; Meguro K
    Age Ageing; 2008 Jul; 37(4):469-73. PubMed ID: 18515851
    [No Abstract]   [Full Text] [Related]  

  • 35. Dementia.
    Warner J; Butler R
    Clin Evid; 2002 Jun; (7):846-66. PubMed ID: 12230710
    [No Abstract]   [Full Text] [Related]  

  • 36. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
    Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
    Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivastigmine for Alzheimer's disease.
    Desai AK; Grossberg GT
    Expert Rev Neurother; 2005 Sep; 5(5):563-80. PubMed ID: 16162080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Factors that modify the natural course of Alzheimer's disease].
    López OL; Becker JT
    Rev Neurol; 2003 Jul 16-31; 37(2):149-55. PubMed ID: 12938075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trials in predementia stages of Alzheimer disease.
    Pillai JA; Cummings JL
    Med Clin North Am; 2013 May; 97(3):439-57. PubMed ID: 23642580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reasons for prescribing cognition enhancers in primary care. Results of a representative survey in Lower Saxony, Germany.
    Stoppe G; Sandholzer H; Staedt J; Winter S; Kiefer J; Rüther E
    Int J Clin Pharmacol Ther; 1995 Sep; 33(9):486-90. PubMed ID: 8520805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.